Call Us Today:
949.200.1600

Photodynamic Therapy (PDT)

Home >Treatment > Nonsurgical Treatment >Photodynamic Therapy (PDT)

Skin-cancer-Specialists-Non-surgical-skin-cancer-treatment-options-photodynamic-therapy-PDT

ABOUT PHOTODYNAMIC THERAPY (PDT)

Photodynamic therapy (PDT) is a unique treatment with clear benefits in non-melanoma skin cancers and precancerous lesions. It is noninvasive, selectively treats abnormal cells, and is relatively inexpensive. Despite these accolades, it is an orphan treatment often rejected for other treatment options.

 

PDT uses porphyrin molecules that have selective penetration of abnormal epidermis. Activated by specific light frequencies, these molecules create a cytotoxic effect, selectively injuring the neoplastic lesions. Two such porphyrins have been utilized – the more common aminolevulinate (ALA, Levulan Kerastick) and possibly the more effective methyl aminolevulinate (MAL, Metvix). FDA-approved only for treatment actinic keratoses, this technology has been applied to treatment of squamous cell carcinoma in situ (SCCis) and superficial basal cell carcinomas (sBCC).

 

Treatment of MAL-PDT is delivered after 3 hours of MAL cream under occlusion, followed by 15 minutes of red light exposure. More common in the US, ALA-PDT uses blue light frequencies. Burning and stinging occur mostly during illumination but can persist for a day. Treatment is usually repeated 1 week later and occasionally in 3 months if complete responses is not achieved. Surface debridement or curettage can improve penetration and efficacy.

 

Summarizing various studies demonstrates efficacy of PDT for AK at 85-90% complete response. Bowen’s disease is cleared in 90% of cases but at 2 years that number is reduced to 68%. Superficial BCC (sBCC) and thin nodular BCC (nBCC) are cured in 75-95% of cases after 3-5 years in various studies. Thick BCC are cleared in 80-85% of cases at 2-4 years.

 

It is fair to say that MAL-PDT achieves a long-term cure for BCC in 80-95% of cases, with the median falling above 85%. Although AK’s achieve a similar success, the available studies for Bowen’s disease show worse long-term cure rate than other pathologies. Cosmetic outcomes are found to be superior to all other treatments.

 

With this data in hand, it is no wonder that British studies form the NHS hospitals and clinics recommend PDT as “the treatment of choice” for primary sBCC in a low risk site (not in central face) that are 2cm and “generally good choice” if < 2cm. They also claim PDT as “generally good choice” in recurrent sBCC in low risk sites. The next category of “fair choice” is reserved for primary nBCC < 2cm in low risk site, primary sBCC < 2cm in high risk site, and primary sBCC 2cm in high risk site.

 

There are a few innovative applications for photodynamic therapy described. PDT has been successfully applied in Basal Cell Nevus Syndrome patients. Unique delivery methods have included intralesional ALA injection and an ALA patch for specific lesions. In addition to fluorescent and LED light sources, IPL (Intense Pulsed Light) has been utilized with success as stand alone and in addition to the traditional light sources.

 

The unique advantages of photodynamic therapy for skin cancers is the ability to treat large areas of field cancerization, the relatively low cost, and the superb cosmetic results. Its under utilization as a modality for non-melanoma skin cancer management in the United States is likely related to economics of the treatment and patient expectations.

Related Articles

Dysplasia-lower-lip-actinic-cheilitis-skin-cancer-SCC
Dysplasia of Lower Lip
HISTORY 51-year-old man presents with one-year history of lower lip nonhealing lesion. The patient has a many year history of extensive sun exposure with scaling and crusting.  A biopsy of the nonhealing lesion showed leukokeratosis with minimal keratinocytic atypia. Excisional biopsy done 11-1-17 showed moderate to focally severe squamous atypia. The patient was then treated…
Read More
SCC-with-Atypia-SCARS-Center-Case-4-Skin-Cancer-And-Reconstructive-Surgery-Center-Orange-County2
LOWER LIP ATYPIA AT MARGINS OF SQUAMOUS CELL CARCINOMA
  HISTORY 89-year-old man presents with several month history of lesion on bottom lip. A biopsy was taken on 8-9-17 and showed severe squamous atypia without ruling out deeper SCC. Excision of lesion done 9-6-17 showed invasive squamous cell carcinoma with foci of moderate squamous dysplasia from 9 to 3 o’clock. Patient has history of…
Read More
Mapping-BCC-with-Confocal-Microscopy-Skin-Cancer-And-Reconstructive-Surgery-Foundation12
MAPPING OF BCC WITH CONFOCAL MICROSCOPY
        HISTORY 63 year old woman diagnosed with recurrence of BCC of left upper lip in 2015 after treatment of Efudex and a surgical excision in 2005. Patient had 3 separate BCC locations in left upper lip.  Due to the size and multifocality of the lesion, patient was treated with Erivedge for 7…
Read More
aktilite_PDT_patient-treatment
Red Light PDT Approval Process
We at Skin Cancer and Reconstructive Surgery Center wanted to upgrade our Photodynamic Therapy (PDT) treatment of AK’s and superficial BCC by switching from the Blu-U light to a red light source. Red light spectrum has been shown to be a deeper penetrating light for photodynamic therapy and, thus, has gained greater worldwide acceptance –…
Read More
Scars Center - Skin Cancer Conference
PDT Across the Atlantic and Medical Economics
Does medical economics bias the community standards for treatment of skin cancers? If the answer is yes, then photodynamic therapy serves as an illustrative example of this bias. Private practice dermatology in the US and National Health Service of UK are practice settings with significantly different economics and also different treatment goals. The one’s is…
Read More

STAY UP TO DATE

Receive research updates, inspiring stories, healthy living tips and more.

Something went wrong. Please check your entries and try again.

FOLLOW US

ELEVATING THE STANDARDS OF SKIN CANCER MANAGEMENT.

© 2018 SCARS Management Services. All rights reserved.